CanProbe is a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of radiopharmaceuticals. CanProbe leverages the strengths of its partners and their affiliates.
CanProbe provides access to specialized expertise that supports the development of new radiopharmaceuticals, with proven experience translating products to the clinical setting, and world-class, GMP, manufacturing capabilities that operate in accordance with FDA, Health Canada and European regulations.
These radiopharmaceuticals are part of an advanced imaging technology that uses medical isotopes to assess and treat patients at a cellular level. Using imaging radiopharmaceuticals, physicians can detect diseases earlier and more accurately monitor the effectiveness of treatments. Targeted therapeutic radiopharmaceuticals can be used to provide personalized treatment of cancers.
The safety and efficacy of these investigational products have not been fully established and they have not been approved by Health Canada as commercial products for medicinal use. These products can only be used under an approved clinical trial application (CTA).
Translational & Clinical Research
Development and commercialization of radiopharmaceuticals in support of clinical and research programs.
Process support and analytical chemistry development for preclinical studies or clinical trials.
Regulatory and clinical research support, including for local researchers using our tracers.
Development and validation of process and methods and GMP manufacturing for clinical trial supply.
Technical transfer of existing methods to enable the manufacture of radiopharmaceuticals for clinical trials.
Access to radioisotopes under the Canadian Nuclear Safety Commission (CNSC) licence such as F-18, Ga-68 or Lu-177. Contact us for the complete list.
Production of CanProbe products and contract manufacturing on behalf of industry partners.
Distribution of radiopharmaceutical products both locally and abroad.
CanProbe has supported over 40 clinical trials with various investigational products
CanProbe has manufactured over 16,000+ patient doses since 2016
CanProbe has relationships with several pharmaceutical clients to manufacture a variety of radiopharmaceuticals
CanProbe is governed by a Board of Directors with members drawn from the University Health Network UHN) and the Centre for Probe Development and Commercialization (CPDC). Board members oversee the joint venture and ensure the successful operation of CanProbe.
CanProbe Board of Directors:
Business Development, Senior Director, CPDC
Senior Director, Techna and Diagnostics Innovation, UHN
Senior Director, Finance & Administration, CPDC
Program Manager, Techna Institute, UHN
Division Head of Molecular Imaging, UHN
Chief Regulatory Officer, CPDC
Site Lead, Techna Institute, UHN
Director, Manufacturing Operations CPDC
Join Our Team
CanProbe is always looking for exceptional people to strengthen our team. If you are interested in joining our team or if you would like to learn more about our current or future opportunities please email us using the button below.
CanProbe is located in Toronto’s Discovery District with facilities in the University Health Network’s Toronto General Hospital.
If you are interested in working with CanProbe to take your radiopharmaceutical study to the next level, contact us at email@example.com